Introduction
Migraine as a neurovascular primary headache disorder is ranked the third most common disease worldwide [1] . On the basis of the latest classification of the International Headache Society, migraine can be divided into episodic (with and without aura) and chronic forms [2] .
The typical features of a migraine attack include the unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity, and association with nausea and/or photophobia and phonophobia [2] . Migraine is a disabling disease, having high socio-economic and personal impacts [3] [4] [5] [6] [7] [8] [9] .
The exact pathomechanism of migraine is still unrevealed. The proposed pathogeneses of the initiation and maintenance of a migraine attack include neuro-vascular alterations, neuropeptide release, neurogenic inflammation, plasma protein extravasation, peripheral and central sensitization, cortical spreading depression (CSD), brain energy deficit, and lesions in the cerebral white matter [10] [11] [12] [13] [14] . The trigeminovascular system (TS) provides an important pain transmission link between the vascular andneuronal elements [15, 16] .
The TS includes the primary sensory pseudounipolar neurons, the cell bodies of which are located in the trigeminal ganglion (TRIG). Their peripheral branches innervate the cranial vessels and meningeal tissues, whereas their central fibers project to the area of the secondorder neurons within the trigeminal nucleus caudalis (TNC) in the brainstem. The information is conveyed to the somatosensory cortex via the third-order neurons located in the thalamus [13, 14] .
The coupling mechanism in the TNC is controlled by descending pathways from distinct brainstem nuclei, e.g., the periaqueductal grey matter (PAG), the nucleus raphe magnus (NRM), the dorsal raphe nucleus (DRN), and the locus coeruleus (LC), collectively referred to as the migraine generators [14, 17] .
It has recently been suggested that glutamate, kynurenines, and pituitary adenylate cyclaseactivating polypeptide (PACAP) may play fundamental roles in the initiation and chronification of migraine headache attacks [18, 19] .
Glutamate plays a pivotal role in neurotransmission, and emerging human and animal data suggest that it is crucial in the pathomechanism of migraine. Indeed, elevated levels of glutamate were detected in the plasma, platelets, and cerebrospinal fluid in migraine patients long after the attacks, supporting the hypothesis of a sustained hyperexcitability in the disease [20] [21] [22] . It is worthy of note that several genetic polymorphisms that affect glutamatergic neurotransmission have been described in migraineurs [23, 24] . It is also important to note F o r R e v i e w O n l y that glutamate receptor antagonists can terminate the aura in patients with familial hemiplegic migraine [25] . Monosodium glutamate is a naturally appearing form of glutamic acid and is able to mimic headache in healthy young volunteers and in rats, an effect mediated by the activation of peripheral N-methyl-D-aspartate (NMDA) receptors and dural vasodilation. Data from the literature demonstrate that glutamate has a prominent role in processes important in migraine generation, such as CSD and the activation and sensitization of the trigeminal system, and it is also present in the migraine generators [26] [27] [28] . Taken together, it seems clear that the role of glutamate is relevant in the pathomechanism of migraine, and its antagonists may have a therapeutic potential.
Kynurenines are less widely known but highly important products of tryptophan (Trp) metabolism [29] . L-kynurenine (L-KYN) and kynurenic acid (KYNA) have neuroprotective effects, whereas 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HA), and quinolinic acid (QIUN) have neurotoxic properties [18, 29] . KYNA is one of the endogenous glutamate receptor antagonists. Preclinical data revealed that L-KYN or synthetic analogues of KYNA can dramatically inhibit the activation of second-order neurons in the TNC in animal models of migraine with electrically or chemically stimulated TS [30] [31] [32] [33] . Furthermore, L-KYN and KYNA can block the process of CSD in experimental conditions [34, 35] . In recent years, clinical studies have demonstrated multiple alterations in the levels of different kynurenine pathway metabolites (e.g., a reduction in the level of L-KYN and an increased level of anthranilic acid (ANA)) in the serum of chronic migraine patients [36] .
PACAP is a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon neuropeptide family and exists in two biologically active forms: PACAP1-27 and PACAP1-38 [37] . The presence of PACAP in human TRIG and TNC has been demonstrated [38, 39] .
The importance of PACAP in migraine has first been pointed out by clinical studies [40] .
Intravenous administration of PACAP1-38 provoked migraine-like attacks accompanied by vasodilation in migraine patients [40, 41] . Experimental data revealed the effect of PACAP on the TS in migraine animal models as well [42, 43] . In line with these, alterations in plasma PACAP1-38 concentration have been demonstrated in migraineurs both ictally and interictally [44] . This paper gives an overview of the currently available data as regards the contribution of the kynurenine pathway and PACAP in the pathogenesis of migraine, with special focus on potential therapeutic implications. to N-formyl-L-kynurenine by opening the Trp ring in a reaction which produces peroxides and highly reactive oxygen and hydroxyl radicals [45] [46] [47] [48] . N-formyl-L-kynurenine is then further degraded by formamidase to form L-KYN. Limited data are available about the biological activity of N-formyl-L-kynurenine, owing to its rapid degradation.
L-KYN has antioxidant properties and can cross the blood-brain barrier. Some 60% of L-KYN present in the CNS is taken up from the blood. L-KYN was demonstrated to be an endogenous ligand of the aryl-hydrocarbon receptor, which has important roles in the immune response and tumor genesis [48] [49] [50] [51] [52] . L-KYN can be metabolized via three different pathways.
The first branch of the kynurenine pathway transforms L-KYN to ANA by kynureninase (Lkynurenine hydrolase). ANA is supposed to have an anti-inflammatory effect via forming a complex with copper and inactivating hydroxyl radicals [53] . ANA is further metabolized to 3-HA by 3-hydroxy-anthranilic acid 3,4-dioxygenase (3-HAO), an iron-dependent enzyme. 3-HAO requires oxygen and sulfhydryl groups for its activation and it is predominantly present in astrocytes within the CNS [54, 55] .
The second branch of the kynurenine pathway starts with the hydroxylation of L-KYN at the third position by the flavin-dependent kynurenine 3-monooxygenase (KMO) to yield 3-HK.
3-HK can be further converted to xanthurenic acid (XA) and 3-HA. 3-HK and 3-HA can increase the level of oxidative stress via the production of free radicals, leading to neuronal damage [56] . Moreover, these molecules can cause excitotoxicity and cell death in neuronal cell cultures [57, 58] . However, ANA is also able to transform into 3-HA, which further transforms into QUIN (pyridine-2,3-dicarboxylic acid). QUIN is an agonist of the NMDA F o r R e v i e w O n l y receptors and can cause neuronal death when administered intrastriatally [57] . It also provokes lipid peroxidation and generates reactive oxygen species [59] . QUIN is then converted to NAD + in the final step of this branch of the kynurenine pathway [60] .
The last branch of the pathway starts with the modification of L-KYN to yield KYNA (4-hydroxi-1H-quinoline-2-carboxylic acid) by kynurenine aminotransferases (KAT)s, which have 4 subtypes with different biochemical profiles [61] . KATs belong to the group of pyridoxal 5-phosphate (PLP)-dependent enzyme family. PLP is connected covalently to the lysine residue of KATs by a Schiff base transaldimine link.
KAT I (glutamine transaminase K or cysteine conjugate beta-lyase) is present in neurons and asytrocytes [62, 63] . KAT II (alpha-aminoadipate aminotransferase) was isolated from rat kidney [64] . Under physiological conditions, KATI and KAT II are proposed to be responsible for the majority of KYNA production in mammalians [61, 63] .
The more recently discovered KATs include KAT III (cysteine conjugate beta-lyase 2), which is present in the kidney, the heart, the liver, and the neuroendocrine tissues, and KAT IV (glutamic-oxaloacetic transaminase 2 or mitochondrial aspartate aminotransferase).
In contrast with QUIN, KYNA has a neuroprotective effect and can mitigate neuronal damage in excitotoxicity and ischemia [65, 66] .
KYNA was discovered by Justus von Liebig in 1853 in urine, and half a century later, the substance was recognized as a bioproduct of Trp metabolism. KYNA is an endogenous metabolite of the kynurenine pathway and behaves as an antagonist at the strychnineinsensitive glycine-binding site and, at higher doses, at the NMDA recognition site [67] . In addition, KYNA exerts mild antagonistic effects on kainate-and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-sensitive glutamate receptors. Furthermore, it is of note that the effect of KYNA on AMPA receptor-mediated action is facilitatory at low concentrations (nanomolar-micromolar) and inhibitory at high concentrations (micromolarmillimolar) [68, 69] . A line of evidence suggested that KYNA is an antagonist at the α7 nicotinic acetylcholine receptor, thereby decreasing the presynaptic release of glutamate;
however, this theory has recently been questioned [70, 71] . In addition, KYNA influences the G protein-coupled receptor 35 (GPR35) and may provoke the generation of inositol trisphosphate, promoting Ca 2+ mobilization. KYNA is present both in the central and peripheral tissues in low concentrations (10-150 nM) , and is generated in the CNS predominantly by glial cells [54, 72] . headache as well neurodegenerative disorders [76] . Recently, our research group have created
hydrochloride (KA1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KA2), which successfully inhibited the trigeminal activation and sensitization in animal models of migraine [77, 78] . A third option is shifting the kynurenine pathway towards the production of KYNA by the use of specific enzyme inhibitors of kynureninase and KMO, the latter being the most comprehensively examined enzyme inhibitor of the pathway, since their inhibition prevents the production of neurotoxic kynurenines, such has 3-HK and QUIN. Supporting this concept, a wealth of animal data confirms that the inhibition of KMO is able to increase the level of KYNA and decrease that of 3-HK and QUIN [79, 80] . The administration of the KMO inhibitor, (R,S)-3,4-dichlorobenzoylalanine (FCE28833A), was effective in increasing KYNA and L-KYN concentrations in the rat brain [81] . Representatives from another group of KMO inhibitors, N-(4-phenylthiazol-2-yl)benzenesulfonamides, were likewise able to raise the level of KYNA in the extracellular hippocampal fluid [82] .
Experimental data with KYNA and its analogues: preclinical and clinical implications
Numerous studies indicate that KYNA and its analogues have antinociceptive effects at the level of both the first-and the second-order sensory neurons [83] . KYNA is capable of [32, 33, 78] . In a recent study, it has been shown that NTG decreased the expression of KAT II, an enzyme converting L-KYN to KYNA, probably implicating decreased KYNA levels as well [87] .
Another experimental setting takes advantage of the electrical stimulation of the TRIG, which also results in decreased KAT immunoreactivity in mast cells, Schwann cells, and dural macrophages [88] .
Several studies have shown that there is a connection between the kynurenines and the CSD.
CSD is a self-propagating process, the electrophysiological correlate of migraine aura, and is able to activate the trigeminal system in experimental animals [89, 90] . L-KYN and KYNA suppressed CSD in a KCl-induced model [34, 35] .
Another model of the trigeminal activation and sensitization takes advantage of the Complete
Freund's Adjuvant (CFA)-induced dural inflammation. In this model, a KYNA analogue was able to abolish the CFA-generated inflammatory response [91] .
To examine trigeminal inflammation and nociception, the orofacial formalin test can also be used, as a stable model for the investigation of somatic pain involving the activation and sensitization of the trigeminal system [92] . In this model, PROB exerted an antinociceptive effect in rats [93] . Notably, PROB is able to increase the concentration of KYNA by inhibiting its excretion in the nervous system, which may contribute to the observed antinociceptive effect [94] . In a most recent study, the effects of two KYNA analogues, KA1
and KA2, were tested in the orofacial formalin model, revealing that the two analogues were able to inhibit the formalin-induced behavioral and morphological changes and increased the concentration of KYNA [95] .
Although the exact mechanism of action of KYNA and its analogues remains unknown, some pieces of the puzzle are starting to fall into place. KYNA can exert its effect both in the periphery and in the CNS. In the periphery, KYNA acts on the glutamate receptors, especially NMDA receptors, localized on certain components of the peripheral nervous system, afferents [96] [97] [98] [99] . As mentioned above, KYNA also has an effect on the GPR35 receptor, which is present in the nociceptive pathway, for example in the dorsal root ganglion; therefore, KYNA may exert its peripheral effect in part on this receptor [100] .
In addition to a peripheral action, KYNA and its analogues have a modulatory potential on second-order neurons as well. KYNA was effective in providing analgesia in the tail-flick, hot-plate, and orofacial formalin tests in mice and rats, as mentioned above. These results are in line with animal studies reporting that kynurenine metabolites can influence pain sensation at the level of the spinal cord [84] . When administered into the spinal cord of cats, KYNA was effective in decreasing the muscular and cutaneous nociceptive reaction of wide dynamic range neurons [101] . In rats, KYNA and its analogues were able to prevent the NTG-or CFAinduced activation and sensitization of the trigeminal system in the TNC, where the trigeminal second-order nociceptive neurons are located [32, 33, 78, 91] . Therefore, KYNA and its derivatives can influence the second-order neurons in the trigeminal system.
There is a number of experimental data suggesting that kynurenines influence the activity of migraine generators, including the NRM, the DRN, the LC, and the PAG. Indeed, KYNA can decrease serotonergic responses of the DRN induced by phasic auditory stimulation or the electrical stimulation of the lateral habenula [102, 103] . KYNA can also diminish the activation of the NRM neurons induced by glutamate, and is able to prevent the activation of noradrenergic neurons in the LC provoked by electrical stimulation of the hindpaw of rats [104, 105] . In addition, the co-administration of KYNA with morphine into the PAG increased the nociceptive effect of morphine [106] .
To date, only few clinical data are available as regards kynurenine pathway alterations in migraine. Recent studies by Curto and her colleagues showed altered serum levels of kynurenine metabolites (L-KYN, KYNA) in patients with chronic migraine and cluster headache [36, 107] . This group was the first to conclude that these two types of primary headaches are both associated with decreased levels of kynurenine metabolites in the peripheral blood.
Summarizing the preclinical and clinical data from the literature, we can conclude that the metabolites of the kynurenine pathway appear to play relevant roles in the pathomechanism of migraine, and they might represent a new potential therapeutic option in the treatment of the disease (Figure 2 ). tetrahydrocannabinol (THC) in squirrel monkeys [109] . In addition, the first discovered endocannabinoid, anandamide, was able to attenuate the NTG-induced decrease in KAT II expression [87] .
Another endogenous system influenced by KYNA is the opioid system. The co-administration of KYNA with morphine raised the acute effect of morphine in rats [106] . Furthermore, KYNA and KA1 reduced the opioid and nociceptin receptor-mediated G-protein activity without demonstrating any affinity towards of opioid receptors [106, 110] , an indirect effect which can be attributed to a decreased G-protein activity or a diminished expression of opioid receptors [110] .
On the other hand, KYNA plays an important role in the regulation of dopaminergic
neurotransmission. An increase in the level of KYNA results in the inhibition of dopamine release; therefore, KYNA is able to influence the levels of dopamine [111] . The decreased level of brain KYNA as a result of the inhibition of KAT II was able to cause an elevation in the extracellular levels of dopamine [112] . In addition, alterations in brain KYNA concentration can be associated with cognitive effects. Indeed, administration of KYNA or L-KYN to rats caused impairments in visuospatial working memory, sensory gating, and contextual learning, phenomena linked to glutamatergic and dopaminergic neurotransmission [113] [114] [115] .
It is also important to note that TDO activity is under the control of blood corticosterone levels and the activity of IDO is regulated by steroids [116, 117] .
The immune system represents another endogenous system which has a strong connection with kynurenines. IDO has essential roles in immune modulation in relation to processes such as infection, transplantation, autoimmunity, and pregnancy. IDO is an immunosuppressive enzyme, with a number of its products being able to inhibit T cell proliferation and activate regulatory T cells; therefore, IDO might have an effect on the negative feedback suppression of T cell response [118] . Importantly, a chronic CNS inflammation might cause an increased activity of IDO by an IFN-γ-mediated process, a phenomenon which might contribute to the pathomechanism of migraine [18] . Notably, not only kynurenines can influence the immune system, but immune molecules such as cytokines can in turn modulate the activity of the kynurenine pathway as well: in particular, tumor necrosis factor-α (TNF-α) and interleukins (IL)s, IL-1, -2, -4, -13, and -23 have a strong modulatory effect on the activation of IDO [118] .
Influencing the kynurenine pathway -chemical and nutritional aspects
Several enzymes of the kynurenine pathway are vitamin-dependent, including KMO, kynureninase, and the KATs [119] . A number of vitamins from the B family can either directly or indirectly upregulate and/or downregulate the activity of the above mentioned enzymes. In particular, vitamin B6 (pyridoxal) has a crucial role in Trp metabolism, being implicated in the physiological function of both the serotonin and kynurenine pathways, and it also functions as a coenzyme of the KATs and kynureninase [120] . These data are in accordance with a recent study demonstrating that the combined application of vitamin B6
and B12 was effective in the reduction of migraine-associated symptoms [121] .
On the other hand, it is well-known that pyridoxal can form chelates with monovalent cations, Recently, a growing attention has been dedicated to the nutritional aspects of kynurenines.
Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol, which can be found in several nutrients, including red wine, peanuts, and cocoa. It has immunomodulatory and anticancer effects [126, 127] . A recent study has shown that resveratrol intake enhanced the activity of IDO in human volunteers [128] . Though in this study, no significant change was observed in the levels of L-KYN, the possibility cannot be excluded that resveratrol can influence the levels of kynurenine metabolites. Furthermore, one should keep in mind that several types of resveratrol in wine-triggered attacks is suggested to be unlikely, and tannins and phenolic flavonoid components of the wine are generally considered to be responsible for the induction of migraine attacks [129] .
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE

Basic biochemical features of PACAP and its receptors
PACAP is a member of the VIP/secretin/glucagon neuropeptide superfamily and is considered to be a 'brain-gut peptide', being widely expressed in the animal and human organisms [37, 130] . PACAP was discovered based on its ability to increase adenylate cyclase activity in rat pituitary cells, and was first isolated from the ovine hypothalamus in 1989 [131] . Genetic studies showed that the human gene of PACAP (ADCYAP1) is localized on the short arm of chromosome 18 (18p11) [132] . The chemical structure of the peptide exists in two biologically active amidated forms, referred to as PACAP1-38 and PACAP1-27, containing 38 and 27 amino acids, respectively (Figure 3 ). PACAP1-38has been revealed to account for some 90% of the total PACAP content in mammalian tissues; however, it is rapidly metabolized and its plasma elimination half-life is very short, being less than 5 min [133] .
PACAP can be found in the central and peripheral nervous systems, in the endocrine and exocrine glands, e.g., pancreas and gonads, as well as in the urogenital and respiratory systems, thereby it functions as a pleiotropic peptide [134] [135] [136] [137] [138] [139] [140] [141] [142] . PACAP has many functions asa hypophysiotropic hormone; furthermore, it also works as a neuromodulator and neurotransmitter within the nervous system [143] [144] [145] [146] [147] In addition, PACAP exerts antiapoptotic, neuroprotective, and differentiation-inducing effects in the developing nervous system [143] [144] [145] [146] [147] [148] . In addition, it plays crucial modulatory and protective roles in the reproductive, cardiovascular, gastrointestinal, and respiratory systems [149] [150] [151] [152] [153] [154] [155] .
The actions of PACAP are mediated via the following three receptors: VPAC 1 (formerly designated the VIP, VIP1 or PACAP type II receptor), VPAC 2 (known as the VIP2 or PACAP type III receptor), and PAC 1 (previously referred to as the PACAP type I receptor).
The PAC 1 receptor has a 1000-fold higher affinity for PACAP1-27 and PACAP1-38 than for VIP [156] [157] [158] . The effect of PACAP on its different receptors induces two substantial signal transduction pathways. Through Gs-or Gq/11-protein activation, a number of kinases exert a (Figure 4 ). An early study showed that about 68% of nociceptin-immunopositive cells in the human TRIG contained PACAP [175] . A human tissue study examining the TNC and the cervical 1-cervical 2 (C 1 -C 2 ) levels of the spinal cord concluded that the moderately dense CGRP-and PACAP-containing fibers can be detected in the vicinity of numerous substance P (SP)-immunoreactive fibers, but VIPimmunoreactive fibers were not observed [134] . Moreover, PACAP was detected in human parasympathetic otic and sphenopalatine ganglia [176] [177] [178] . PACAP1-38 immunoreactivity was found in neurons and satellite glia cells in rat sphenopalatine ganglia [178] . A broad range of data suggests that PACAP functions as an integrator of nociceptive and sensitization processes, besides being involved in neurogenic inflammation [164, 166, 170, 179] . PACAP and glutamate were both detected in the TRIG of rhesus monkeys and rats [180] .
Link between PACAP and migraine The exact pathomechanism of migraine is unknown, but the activation and sensitization of the TS are among the leading hypotheses [13, 14] . There is a number of evidence highlighting the possible role of PACAP in the pathogenesis of migraine. The first human evidence that demonstrated the significance of PACAP in migraine was published by Schytz et al. in 2009 [40] . Intravenous infusion of PACAP1-38 caused delayed migraine-like attacks, similarly to the effect of nitroglycerin infusion in migraineurs [40, 181, 182] . Moreover, the decrease of the mean blood flow velocity in the middle cerebral artery and the increase of the diameter of the superficial temporal artery were also observed in the PACAP study of migraineurs [40] .
After these promising clinical data, preclinical animal studies were performed to explain the background of the effect of PACAP in the human body [42, 43] . After chemical (by nitroglycerin) and electrical (at the TRIG) stimulation of TS, PACAP1-27 and PACAP1-38immunoreactivity were found significantly increased in TNC in rats. Even more, PACAP1-38 elevation was found in the plasma after the electrical stimulation of the TRIG in rats [42] .
PACAP-deficient mice displayed reduced light-aversive behavior (photophobia), and decreased meningeal blood flow and c-fos expression were detected in the TRIG and TNC relative to wild-type mice after nitroglycerin-induced TS activation [43] . Neurogenic inflammation and mast cell degranulation also take part in the process of migraine [183, 184] .
After mast cell degranulation, the released histamine may induce a long-lasting activation of the TS. It has been demonstrated that vasodilation induced by systemically administered PACAP1-38 was diminished in mastocyte-depleted and antihistamine-pretreated rats [185] .
PACAP has the capability to release histamine from rat peritoneal or human skin mast cells [186, 187] . VPAC1 receptor is expressed on mast cells [188] . The importance of mast cell degranulation within the dura is given by its possible association with the activation of peripheral trigeminal fibers, which leads to peripheral sensitization [184, 189, 190] .
Electrophysiological studies proved that PACAP1-38 could cause delayed activation and sensitization of second-order neurons in the trigemino-cervical complex, in a process mediated by neuronal PAC 1 receptor in rats [161] . Magnetic resonance angiography of selective extra-and intracranial arteries in humans revealed marked and long-lasting dilation of extracranial arteries after PACAP1-38 infusion [41] . Elevated plasma PACAP1-38 immunoreactivity was detected in the spontaneous ictal period compared to the interictal phase of migraineurs [44] . Interestingly, similar data were found in episodic cluster headache patients [191] . However, in tension-type headache patients, interictal plasma PACAP level was unchanged, whereas in the same phase, it was found decreased in migraineurs [192] . A recent clinical study revealed that PACAP mRNA expression in the peripheral blood 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r R e v i e w O n l y mononuclear cells in migraine patients was significantly reduced compared to tension-type headache, cluster headache, or medication overuse headache patient groups [193] . During the ictal period, PACAP plasma level in the external jugular vein was found elevated, which alteration was reduced 1 hour after treatment with sumatriptan, a potent acute anti migraine drug [194] . In a clinical study, previously genotyped patients with migraine without aura were infused by PACAP1-38, which resulted in delayed migraine-like attacks and elevated plasma levels of VIP, prolactin, S100 calcium binding protein B, and thyroid-stimulating hormone [195] . This finding pointed out that PACAP may activate parasympathetic nerve endings, causing VIP release [195] . However, the presence of the MEF2D gene variant (rs2274316) was not associated with pre-ictal alterations in neuropeptide levels in the plasma, and neither a high family load nor the presence of this risk allele influenced the migraine response to PACAP1-38 infusion [195, 196] . A resting-state functional MRI study demonstrated that intravenously administered PACAP1-38-induced migraine attacks are associated with altered brain network connectivity (in terms of salience, sensorimotor, and default mode networks) [197] .
Summary
Theoretically, PACAP may be released from the peripheral and central terminals of the trigeminal nerve endings. Peripherally released PACAP may cause vasodilation and mast cell degranulation, resulting in peripheral sensitization. On the other hand, centrally released PACAP may lead to the activation of second-order sensory neurons in the TNC in a process mediated by the PAC1 receptor, which leads to central sensitization. Both the peripheral and the central sensitization processes take part in the initiation of migraine attacks [19, 184, [198] [199] [200] [201] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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